Conserved aromatic residues in the transmembrane region VI of the V(1a) vasopressin receptor differentiate agonist vs. antagonist ligand binding

European Journal of Biochemistry

Volumn 267, Issue 13, 2000, Pages 4253-4263

  Cotte, Nathalie ^a   Balestre, Marie Noëlle ^a   Aumelas, André ^b   Mahé, Eve ^a   Phalipou, Sylvie ^a   Morin, Denis ^a   Hibert, Marcel ^c   Manning, Maurice ^d   Durroux, Thierry ^a   Barberis, Claude ^a   Mouillac, Bernard ^a  

^a INSERM   (France)

^b CENTRE DE BIOCHIMIE STRUCTURALE   (France)

^c Laboratoire de Pharmacochimie   (France)

^d MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Antagonist binding sites; Signal transduction; Site directed mutagenesis; Three dimensional model; Vasopressin receptors

Indexed keywords

VASOPRESSIN RECEPTOR;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; HYDROPHILICITY; LIGAND BINDING; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; RECEPTOR BINDING; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS;

ANIMALIA;

EID: 0033944796     PISSN: 00142956     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1432-1033.2000.01472.x     Document Type: Article

References (41)

1. 1. Schwartz, T.W. (1994) Locating ligand-binding sites in 7TM receptors by protein engineering. Curr. Opin. Biotechnol. 5, 434-444.
2. 2. Strader, C.D., Fong, T.M., Graziano, M.P. & Tota, M.R. (1995) The family of G protein-coupled receptors. FASEB. J. 9, 745-754.
3. 3. Ji, T.H., Grossmann, M. & Ji, I. (1998) G protein-coupled receptors. Diversity of receptor-ligand interactions. J. Biol. Chem. 273, 17299-17302.
4. 4. Mouillac, B., Chini, B., Balestre, M.N., Elands, J., Trumpp-Kallmeyer, S., Hoflack, J., Hibert, M., Jard, S. & Barberis, C. (1995) The binding site of neuropeptide vasopressin V1a receptor: evidence for a major localization within transmembrane regions. J. Biol. Chem. 270, 25771-25777.
5. 5. Strader, C.D., Sigal, I.S., Register, R.B., Candelore, M.R., Rands, E. & Dixon, R.A.F. (1987) Identification of residues required for ligand binding to the β-adrenergic receptor. Proc. Natl Acad. Sci. USA. 84, 4384-4388.
6. 6. Czaplewski, C., Kazmierkiewicz, R. & Ciarkowski, J. (1998) Molecular modeling of the human vasopressin V2 receptor/agonist complex. J. Comp.-Aid. Mol Design 12, 275-287.
7. 7. Chini, B., Mouillac, B., Ala, Y., Balestre, M.N., Trumpp-Kallmeyer, S., Hoflack, J., Elands, J., Hibert, M., Manning, M., Jard, S. & Barberis, C. (1995) Ty115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor. EMBO J. 14, 2176-2182.
8. 8. Ufer, E., Postina, R., Gorbulev, V. & Fahrenholz, F. (1995) An extracellular residue determines the agonist specificity of V2 vasopressin receptors. FEBS Lett. 362, 19-23.
9. 9. Cotte, N., Balestre, M.N., Phalipou, S., Hibert, M., Manning, M., Barberis, C. & Mouillac, B. (1998) Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor. J. Biol. Chem. 273, 29462-29468.
10. 10. Chini, B., Mouillac, B., Balestre, M.N., Trumpp-Kallmeyer, S., Hoflack, J., Hibert, M., Andriolo, M., Pupier, S., Jard, S. & Barberis, C. (1996) Two aromatic residues regulate the response of the human oxytocin receptor to the partial agonist arginine vasopressin. FEBS Lett. 397, 201-206.
11. 8]vasotocin receptor. Proc. Natl Acad. Sci. USA. 93, 6907-6912.
12. 12. Manning, M. & Sawyer, W.H. (1993) Design, synthesis and some uses of receptor-specific agonists and antagonists of vasopressin and oxytocin. J. Receptor Res. 13, 195-214.
13. 13. Serradeil-Le Gal, C., Wagnon, J., Garcia, C., Lacour, C., Guiraudou, P., Christophe, B., Villanova, G., Nisato, D., Maffrand, J.P., Le Fur, G., Guillon, G., Cantau, B., Barberis, C., Trueba, M., Ala, Y. & Jard, S. (1993) Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J. Clin. Invest. 92, 224-231.
14. 14. Yamamura, Y., Ogawa, H., Yamashita, H., Chihara, T., Miyamoto, H., Nakamura, S., Onogawa, T., Yamashita, T., Hosokawa, T., Mori, T., Tominaga, M. & Yabuuchi, Y. (1992) Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br. J. Pharmacol. 105, 787-791.
15. 15. Postina, R., Kojro, E. & Fahrenholz, F. (1996) Separate agonist and peptide antagonist binding sites of the oxytocin receptor defined by their transfer into the V2 vasopressin receptor. J. Biol. Chem. 271, 31593-31601.
16. 16. Phalipou, S., Cotte, N., Carnazzi, E., Seyer, R., Mahé, E., Jard, S., Barberis, C. & Mouillac, B. (1997) Mapping peptide-binding domains of the human V1a vasopressin receptor with a photo-activatable linear peptide antagonist. J. Biol. Chem. 272, 26536-26544.
17. 17. Phalipou, S., Seyer, R., Cotte, N., Breton, C., Barberis, C., Hibert, M. & Mouillac, B. (1999) Docking of linear peptide antagonists into the human V1a vasopressin receptor: identification of binding domains by photoaffininty labeling. J. Biol. Chem. 274, 23316-23327.
18. 18. Kruszynski, M., Lammek, B., Manning, M., Seto, J., Haldar, J. & Sawyer, W.H. (1980) [1-(β-mercapto-β,β-cyclopentamethylenepropionic acid),2-(O-methyl)-tyrosine]arginine vasopressin and [1-(β-mercapto-β,β-cyclopentamethylenepropionic acid)]arginine vasopressin, two highly potent antagonists of the vasopressor response to arginine vasopressin. J. Med. Chem. 23, 364-368.
19. 19. Gavras, H., Ribeiro, A.B., Kohlmann, O., Saragoca, M., Mulinari, R.A., Ramos, O. & Gavras, I. (1984) Effects of a specific inhibitor of the vascular action of vasopressin in humans. Hypertension 6, I156-I160.
20. 20. Schmidt, J.M., Ohlenschläger, O., Rüterjans, H., Grzonka, Z., Kojro, E., Pavo, I. & Fahrenholz, F. (1991) Conformation of [8-arginine]vasopressin and V1 antagonists in dimethyl sulfoxide solution derived from two-dimensional NMR spectroscopy and molecular dynamics simulation. Eur. J. Biochem. 201, 355-371.
21. 21. Ala, Y., Morin, D., Mouillac, B., Sabatier, N., Vargas, R., Cotte, N., Déchaux, M., Antignac, C., Arthus, M.F., Lonergan, M., Turner, M.S., Balestre, M.N., Alonso, G., Hibert, M., Barberis, C., Hendy, G.H., Bichet, D.G. & Jard, S. (1998) Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus: molecular basis of a mild clinical phenotype. J. Am. Soc. Nephrol. 9, 1861-1872.
22. 2]OVT: a selective oxytocin receptor ligand. Eur. J. Pharmacol. 147, 197-207.
23. 23. Barberis, C., Balestre, M.N., Jard, S., Tribollet, E., Arsenejevic, Y., Dreifuss, J.J., Bankowski, K., Manning, M., Chan, W.Y., Schlosser, S.S., Holsboer, F. & Elands, J. (1995) Characterization of a novel, linear radioiodinated vasopressin antagonist: an excellent radioligand for vasopressin V1a receptors. Neuroendocrinology 62, 135-146.
24. 24. Schall, T.J., Lewis, M., Koller, K.J., Lee, A., Rice, G.C., Wong, G.H.W., Gatanaga, T., Granger, G.A., Lentz, R., Raab, H., Kohr, W.J. & Goeddel, D.V. (1990) Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 61, 361-370.
25. 25. Morin, D., Cotte, N., Balestre, M.N., Mouillac, B., Manning, M., Breton, C. & Barberis, C. (1998) The D136A mutation of the V2 vasopressin receptor induces a constitutive activity which permits discrimination between antagonists with partial agonist and inverse agonist activities. FEBS Lett. 441, 470-475.
26. 26. Munson, P.J. & Rodbard, D. (1980) Ligand: a versatile computerized approach for the characterization of ligand binding systems. Anal. Biochem. 107, 220-239.
27. 27. Hibert, M., Trumpp-Kallmeyer, S., Bruinvels, A. & Hoflack, J. (1991) Three-dimensional models of neurotransmitter G-binding protein-coupled receptors. Mol. Pharmacol. 40, 8-15.
28. 28. Trumpp-Kallmeyer, S., Hoflack, J., Bruinvels, A. & Hibert, M. (1992) Modeling of G protein-coupled receptors: application to dopamine, adrenaline, serotonin, acetylcholine, and mammalian opsin receptors. J. Med. Chem. 35, 3448-3462.
29. 29. Schertler, G.F., Villa, C. & Henderson, R. (1993) Projection structure of rhodopsin. Nature 362, 770-772.
30. 30. Aurell, C.J., Bengtsson, B., Ekholm, K., Kasprzykowska, R., Nilsson, A., Persson, R., Trojnar, J., Abbe, M. & Melin, P. (1991) Development of vasopressor specific vasotocin analogues with prolonged effects. In Peptides (Giralt, E. & Andreu, D., eds), pp. 671-673. ESCOM Science Publishers, Leiden, Germany.
31. 31. Serradeil-Le Gal, C., Lacour, C., Valette, G., Garcia, G., Foulon, L., Galindo, G., Bankir, L., Pouzet, B., Guillon, G., Barberis, C., Chicot, D., Jard, S., Vilain, P., Garcia, C., Marty, E., Raufaste, D., Brossard, G., Nisato, D., Maffrand, J.P. & Le Fur, G. (1996) Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J. Clin. Invest. 98, 2729-2738.
32. 1). J. Biol. Chem. 270, 14024-14030.
33. 33. Befort, K., Tabbara, L., Kling, D., Maigret, B. & Kieffer, B.L. (1996) Role of aromatic transmembrane residues of the d-opioid receptor in ligand recognition. J. Biol. Chem. 271, 10161-10168.
34. 34. Huang, R.-R.C., Vicario, P.P., Strader, C.D. & Fong, T.M. (1995) Identification of residues involved in ligand binding to the neurokinin-2 receptor. Biochemistry 34, 10048-10055.
35. 35. Strader, C.D., Fong, T.M., Tota, M.R. & Underwood, D. (1994) Structure and function of G protein-coupled receptors. Annu. Rev. Biochem. 63, 101-132.
36. 36. Strader, C.D., Sigal, I.S., Candelore, M.R., Rands, E., Hill, W.S. & Dixon, R.A.F. (1988) Conserved aspartic acid residues 79 and 113 of the β-adrenergic receptor have different roles in receptor function. J. Biol. Chem. 263, 10267-10271.
37. 37. Suryanarayana, S. & Kobilka, B.K. (1993) Amino acid substitutions at position 312 in the seventh hydrophobic segment of the β2-adrenergic modify ligand-binding selectivity. Mol. Pharmacol. 44, 111-114.
38. 38. Gether, U. & Kobilka, B.K. (1998) G protein-coupled receptors. Mechanism of agonist activation. J. Biol. Chem. 273, 17979-17982.
39. 39. Kudo, M., Osuga, Y., Kobilka, B.K. & Hsueh, A.J.W. (1996) Transmembrane regions V and VI of the luteinizing hormone receptor are required for constitutive activation by a mutation in the third intracellular loop. J. Biol. Chem. 271, 22470-22478.
40. 2A receptor. J. Biol. Chem. 270, 16683-16688.
41. 41. Robinson, P.R., Cohen, G.B., Zhukovsky, E.A. & Oprian, D.D. (1992) Constitutively active mutants of rhodopsin. Neuron 9, 719-725.